Vaccine Targeting Equipment & Supplies
14 equipment items found
Manufactured by:DSS Takara Bio India Pvt Ltd based inNew Delhi, INDIA
SARS-CoV-2 research is happening at breakneck speed, and scientists are trying to identify epitopes that could trigger an immune response to the virus, an important step in the development of novel vaccines. Takara Bio offers an array of innovative technologies to support this endeavor. The development of a vaccine involves an analysis of the viral and host ...
Manufactured by:EnGen Bio LLC based inREDWOOD CITY, CALIFORNIA (USA)
While it has been believed that M1 is completely protected by the lipid membrane, we have discovered that a portion of it is in fact exposed and accessible to monoclonal antibody binding, and therefore represents a vaccine target. We have determined that it is critical to engineer the immunogen to allow the immune system to focus its response on the ...
Manufactured by:Vitruvian BioMedical, Inc. based inAddison, TEXAS (USA)
VITRUVIAN has obtained the Exclusive Global License for a Therapeutic Vaccine for the Prevention of Alzheimer's Disease. YM7555 - Alzheimer’s Disease Therapeutic Vaccine targeting ABeta and TAU. VITRUVIAN has received an Exclusive Global License for YM7555 which is a Therapeutic Vaccine technology for the prevention of ...
Manufactured by:Calder Biosciences, Inc. based inBrooklyn, NEW YORK (USA)
Targeted approach, focused responses. Substantially reduced risk vis-à-vis other modalities. Successful recombinant subunit vaccines elicit the highest. Ab responses; Shingrix vs. Zostavax, Gardasil, HBsAg (Recombivax, Engerix, Heplisav), HAV (Vaqta, ...
Manufactured by:Virometix AG based inSchlieren, SWITZERLAND
Virometix is focusing on the development of vaccine candidates with broad protection against a diverse number of coronaviruses. Our epitope-focused SVLP-based vaccine aims to target specific regions of the Receptor Binding Domain (RBD) of the Spike protein. Proof-of-concept studies are currently ongoing using SARS-CoV-2, where five Synthetic ...
Manufactured by:Auro Vaccines LLC based inPearl River, NEW YORK (USA)
Auro Vaccines is developing a GeneVav prime/VesiculoVax™ boost therapeutic vaccine that targets all HCV genotypes for use as an adjunct to drug ...
Manufactured by:Auro Vaccines LLC based inPearl River, NEW YORK (USA)
Auro Vaccines has also developed a GeneVax prime/VesiculoVax boost therapeutic vaccine that targets all eight HBV genotypes for use as an adjunct to drug ...
by:CuraVac Europe S.A. based inRixensart, BELGIUM
CuraVac is a clinical-stage biotechnology company developing the medical and commercial potential of a revolutionary technique for the production of specific Therapeutic Vaccines (or Active Targeted Immunotherapies) for autoimmune ...
by:BacVax, Inc. based inPhoenix, ARIZONA (USA)
Current commercial bacterial vaccines use toxin neutralization, capsule targeting, or multiple proteins. While these methods may work in some circumstances, many bacteria do not have toxin or capsule targets, and using several proteins in a vaccine is expensive and opens the opportunity for genetic escape by the bacteria. ...
Manufactured by:Hygieia Biological Laboratories based inWoodland, CALIFORNIA (USA)
Preventative health including vaccination is a key focus of good animal management. Hygieia offers inactivated autogenous bacterins and vaccines which are custom manufactured from disease agents specifically found at an individual ranch, zoo, or other animal facility. This allows the producer or owner to tailor a vaccine formulation to ...
by:Evaxion Biotech A/S based inHørsholm, DENMARK
EDEN is our second AI platform that rapidly identifies novel, highly protective antigens for the use in pathogen-specific prophylactic vaccines against bacteria. EDEN has been designed to rapidly identify those antigens that will trigger a robust protective immune response against almost any bacterial infectious disease. In addition, EDEN redesigns identified antigens to optimize their antigenic ...
Manufactured by:Elicio Therapeutics based inBoston, MASSACHUSETTS (USA)
ELI-007 is a multivalent lymph node–targeted AMP peptide vaccine developed to target BRAF gene mutations. The BRAF gene is part of an intracellular signaling pathway that drives cell growth and division.1 BRAF mutations can lead to uncontrolled cell growth and ultimately cancer. BRAF mutations are present in multiple types of ...
by:NEC OncoImmunity AS based inOslo, NORWAY
Recent advances in the field of immuno-oncology have established that mutated antigens (neoantigens), are viable targets of the immune system, potentially specific to each individual cancer patient. This plus many other breakthroughs in immuno-oncology and the rapid advances in next generation sequencing (NGS), opens up exciting new opportunities to harness neoantigens for their therapeutic and ...
by:CuraVac Europe S.A. based inRixensart, BELGIUM
The MYASTERIX project (2013 – 2018) advanced a Therapeutic Vaccine candidate (designated orphan drug) indicated for myasthenia gravis (MG) to clinical proof of concept ...